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MICROORGANISMS AND THE PATENT OFFICE:
TO DEPOSIT OR NOT TO DEPOSIT,
THAT IS THE QUESTION
INTRODUCTION
The revolution in biotechnology1 is one of the most important
developments affecting industry in the twentieth century.2 New tech-
niques have been developed to create novel life forms. 3 Many compan-
ies have been formed to exploit these advances in biotechnology, 4
while other corporations are expanding into this area.5 To protect
their investments in these new ventures, companies have relied on the
seventeen-year monopoly granted inventors under the Patent Act of
1952 (Act).6
1. Biotechnology, the use of living organisms in a manufacturing or productive
role, is actually a new term for an old industry. People have always sought to use the
abilities and characteristics of other organisms to improve society. For example,
through the development of breeding techniques and the cultivation of various
hybrid animals and plants, existing species have been improved and new species
developed. See I. Cooper, Biotechnology and the Law § 1.01, at 1-1 (1982); Demain,
Industrial Microbiology, 214 Science 987, 991-94 (1981).
2. Biotech Comes of Age, Bus. Wk., Jan. 23, 1984, at 84, col. 1 (technological
revolution that may rival even the development of the computer).
;3. See I. Cooper, supra note 1, § 1.01, at 1-1; Blattner, Biological Frontiers, 222
Science 719, 719 (1983); Falkinham, Principles of Genetic Engineering, in Geneti-
cally Engineered Microorganisms & Cells: The Law & Business II-1 to -24 (I. Kayton
ed. 1981).
4. Since 1980, over 100 companies have been formed to exploit the new technol-
ogy. Norman, Another Biotechnology Company Bites the Dust, 217 Science 1016
(1982); Biotech Come of Age, Bus. Wk., Jan. 23, 1984, at 84, col. 1.
5. See, e.g., Culliton, Monsanto Gives Washington U. $23.5 Million, 216 Sci-
ence 1295 (1982); Walsh, Cornell, Three Companies Plight Biotech Troth, 220
Science 287 (1983). The increased interest in biotechnology is not limited to the
United States. See Dickson, German Firms Move Into Biotechnology, 218 Science
1287 (1982); Dickson, France Boosts Biotechnology, 217 Science 516 (1982); Sch-
meck, Report Says Japan Could Lead in Commercial Biotechnology, N.Y. Times,
Jan. 27, 1984, at A9, col. 3.
6. 35 U.S.C. §§ 1-376 (1976). The seventeen-year monopoly allows the inventor
to exclude all others from making, using or selling his invention. 35 U.S.C. § 154
(1976). The cost of developing microorganisms is very high. "Without a proprietary
position, such as a patent right, few industrial firms will be keen on spending millions
of dollars for research." I. Cooper, supra note 1, § 1.02, at 1-15. This is analogous to
the situation in the pharmaceutical industry where, without patent protection, the
development of new drugs would be unprofitable. Id. at 1-15 n.16. The availability
of patents to cover the newly developed microorganisms will encourage more invest-
ment because of the greater chance for a sizable return. Id. at 1-15 & n. 16.
Some of the patents that have been obtained by companies working in biotechnol-
ogy include: U.S. Pat. No. 4,362,816 (1982) (process for creating new microorga-
nisms that can produce insulin, assigned to The Upjohn Company); U.S. Pat. No.
4,350,769 (1982) (microorganism that produces a thickening agent for aqueous sys-
DEPOSIT REQUIREMENT
Prior to the Supreme Court's 1980 decision in Diamond v. Chakra-
barty,7 a living microorganism could not be patented because the
organism was a "work of nature."8 The inventor was limited to claim-
ing such inventions as a process, method or mixture using the microor-
ganismA In Chakrabarty, however, the Court held that the man-
made living bacteria in question was patentable subject matter. 10 The
invention was found to be patentable because the bacteria had "mark-
edly different characteristics from any found in nature and [had]...
the potential for significant utility."" Additionally, the discovery was
the inventor's, not "nature's handiwork." 12 This decision expanded the
tems, assigned to Merck & Co., Inc.); U.S. Pat. No. 4,259,444 (1981) (microorga-
nism that can digest crude oil, assigned to the General Electric Company).
7. 447 U.S. 303 (1980).
8. Id. at 309-10; accord Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S.
127 (1948). In Funk Bros., the Supreme Court held a patent claiming a mixture of
bacteria invalid for want of invention because one could not claim or patent a
natural phenomenon. Id. at 131-32. Although the organisms expressed a trait not
exhibited in nature, these were natural properties of the organisms and the discovery
of the traits did not warrant the issuance of a patent. Id. at 130-31.
9. See, e.g., Tabuchi v. Nubel, 559 F.2d 1183, 1184 (C.C.P.A. 1977) (patent
allowed for a method that produced citric acid using a yeast from the strain Can-
dida); Ex parte Schmidt-Kastner, 153 U.S.P.Q. (BNA) 473, 474 (Pat. Bd. App. 1963)
(patent allowed for a process the production of actinomycin F1 using a novel micro-
organism); U.S. Pat. No. 1,260,899, at 3 (1918) (patent allowed for lactic acid
bacillus mixed with inert material).
10. Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980). In Chakrabarty's patent
applications, in addition to claiming a process using a new microorganism and the
process creating the new organism, he claimed a new form of the bacterial genus
Pseudomonas capable of digesting crude oil. In re Chakrabarty, 197 U.S.P.Q. (BNA)
72, 73 (C.C.P.A.), cert. dismissed, 439 U.S. 801 (1978), aff'd on rehearing sub nom.
In re Bergy, 596 F.2d 952 (C.C.P.A. 1979), aff'd sub nom. Diamond v. Chakra-
barty, 447 U.S. 303 (1980). The patent examiner rejected the claim to the microorga-
nism because, in his opinion, the organisms were "products of nature" and as such
could not be patented. 197 U.S.P.Q. (BNA) at 74. The Patent and Trademark Office
Board of Appeals affirmed the rejection on the grounds that a living organism could
not be the proper subject of a patent. Id. The Court of Customs and Patent Appeals
(now part of the Court of Appeals for the Federal Circuit) reversed, holding that
living matter could be the subject of a patent. Id. at 75.
11. 447 U.S. at 310.
12. Id. The Court did not address the question whether naturally occurring
microorganisms were the proper subject of a patent. A companion case, Parker v.
Bergy, 444 U.S. 924 (1980), raised the issue, but the appeal was dismissed as moot
when Bergy withdrew the claim to the microorganism. Diamond v. Chakrabarty,
444 U.S. 1028 (1980); see I. Cooper, supra note 1, § 2.08, at 2-23. The court below,
however, in dicta, had found the new organism isolated from natuie to be the proper
subject of a patent because what was claimed was a biologically pure culture of the
organism and the organism did not exist in a pure state in nature. In re Bergy, 596
F.2d 952, 976 (C.C.P.A. 1979), dismissed as moot sub nom. Diamond v. Chakra-
barty, 444 U.S. 1028 (1980). The Patent Office appears to have adopted this position
as it has allowed patents claiming biologically pure cultures of microorganisms
isolated from nature. See, e.g., U.S. Pat. No. 4,371,622 (1983) (microorganism
isolated from Danubian mud); U.S. Pat. No. 4,328,316 (1982) (microorganisms
isolated from Indian soil); U.S. Pat. No. 4,315,989 (1982) (microorganism isolated
from soil).
FORDHAM LAW REVIEW [Vol. 52
protection that an inventor can obtain for a new microorganism and
has spurred the increased commercial interest in biotechnology.
13
An inventor claiming or using microorganisms faces an unusual
problem in satisfying the "enablement" requirement of the Act. 14 The
Act requires an inventor to include in his patent application "a written
description of the invention, and of the manner and process of making
and using it, in such full, clear, concise, and exact terms as to enable
any person skilled in the art . . . to make and use the same."' 5 As a
result, the enablement requirement helps fulfill the overall purpose of
the Act which is "To promote the Progress of Science and the useful
Arts"16 by encouraging inventors to share their acquired knowledge
with the public. 17
A writing, known as the specification, normally satisfies the enable-
ment requirement.' If a patent claims or uses a microorganism,
however, a specification alone may not necessarily satisfy the enable-
ment requirement. 9 To solve this problem, the Patent and Trade-
mark Office (Patent Office) and the courts have developed a deposit
requirement for patents involving microorganisms. 20 If a patent relies
on a microorganism that is not known or readily available to the
public, a culture or sample of the microorganism must be placed "in a
depository affording permanence of the deposit and ready accessibility
thereto by the public if a patent is granted. '21 In this manner, enable-
ment is accomplished because using both the specification and the
13. See supra notes 4-6 and accompanying text.
14. See In re Argoudelis, 434 F.2d 1390, 1392-93 (C.C.P.A. 1970) (written
description of the inventor's process alone insufficient because of the unique aspect of
using microorganism); Ex parte Kropp, 143 U.S.P.Q. (BNA) 148, 152 (Pat. Bd. App.
1959) (same).
15. 35 U.S.C. § 112 (1976).
16. The purpose of the Act is found in U.S. Const. art. I, § 8, cl. 8.
17. Sony Corp. of Am. v. Universal City Studios, 52 U.S.L.W. 4090, 4093 (U.S.
Jan. 17, 1984) (The purpose of the patent and copyright laws is to motivate inventors
and writers by granting them a limited monopoly and to allow public access to the
products of their genius when the monopoly expires.); A.F. Stoddard & Co. v. Dann,
195 U.S.P.Q. (BNA) 97, 103 (D.C. Cir. 1977) ("The quid pro quo which supports the
patent grant is the requirement of a full disclosure regarding the invention; indeed,
the very purpose of the patent system is to encourage disclosures."); Flick-Reedy
Corp. v. Hydro-Line Mfg. Co., 146 U.S.P.Q. (BNA) 694, 697 (7th Cir. 1965) (same),
cert. denied, 383 U.S. 958 (1966); Ex parte Hull, 191 U.S.P.Q. (BNA) 157, 159 (Pat.
Bd. App. 1975) (same).
18. See 35 U.S.C. § 112 (1976). A specification must be included in all patent
applications. Id. § 111 (1976).
19. In re Argoudelis, 434 F.2d 1390, 1392-93 (C.C.P.A. 1970); Ex parte Kropp,
143 U.S.P.Q. (BNA) 148, 152 (Pat. Bd. App. 1959).
20. In re Argoudelis, 434 F.2d 1390, 1392-93 (C.qCP.A. 1970); Manual of Patent
Examining Procedure § 608.01(p)(C) (1981) [hereinafter cited as MPEP].
21. MPEP, supra note 20, § 608.01(p)(C).
DEPOSIT REQUIREMENT
microorganism, a person skilled in the art can make and use the
claimed invention.
-2 2
Since the development of the deposit requirement, significant
changes in technology have occurred. 23 Techniques have been devel-
oped by which new organisms can be created.2 4 Using these tech-
niques, it is possible for another scientist to faithfully duplicate a
process and thereby consistently achieve the same results as the origi-
nal inventor.25 Thus, it may be possible to develop the microorga-
nism '8 based on the specification alone. 27 Additionally, problems such
as the cost of the deposit and the lack of a clear standard for the
deposit have arisen. As a result, if the process can be faithfully repro-
duced, a deposit should not be required. When a deposit is needed,
the requirement should be modified.
This Note addresses the question of when a deposit should be re-
quired for patents involving microorganisms. Part I explores the his-
tory and purpose of the deposit requirement. Part II describes recent
changes in technology. Part III examines some of the problems of the
deposit requirement. In conclusion, Part IV offers suggestions to over-
come these problems.
I. THE DEPOSIT REQUIREMENT
Inventions using microorganisms have been patented for over one
hundred years.2 8 The patents usually claimed new processes, 29 meth-
ods30 or mixtures3' using known or readily-available microorga-
nisms.3 2 In the 1940's and the 1950's, with the development of new
22. In re Argoudelis, 434 F.2d 1390, 1393 (C.C.P.A. 1970).
23. See infra pt. II.
24. See infra pt. II.
25. See infra note 76 and accompanying text.
26. While this Note focuses primarily on patents claiming microorganisms such
as bacteria, utility patents claiming other living organisms such as plants may be
subject to the deposit requirement as well. Neagley, Jeffrey & Diepenbrock, Section
101 Plant Patents-Panacea or Pitfall?, in 1 Am. Pat. Law Ass'n Selected Legal
Papers Al, A25 (1983); see U.S. Pat. No. 4,378,655 (1983) (utility patent on new
variety of plant in which a deposit was made of the seed from the starting organism).
Thus, the discussion of the deposit requirement applies to those patents as well as
those claiming microorganisms.
27. See infra note 76 and accompanying text.
28. In 1873, Pasteur patented a biologically pure culture of yeast as a new article
of manufacture. U.S. Pat. No. 141,072 (1873).
29. E.g., In re Mancy, 182 U.S.P.Q. (BNA) 303, 304 (C.C.P.A. 1974); Ex parte
Schmidt-Kastner, 153 U.S.P.Q. (BNA) 473, 473-74 (Pat. Bd. App. 1963).
30. See Tabuchi v. Nubel, 559 F.2d 1183, 1184 (C.C.P.A. 1977).
31. E.g., U.S. Pat. No. 1,260,899 (1918) (lactic acid bacillus mixed with inert
material); U.S. Pat. No. 952,418 (1910) (bacteria mixed with cocoa).
32. See Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 129 (1948) (six
microorganisms used in the mixture were well-known in the art).
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antibiotics, inventors began to use new and rare microorganisms in
the processes or methods claimed in their applications.3 3 Because the
organisms used were not generally available to the public, these pat-
ent applications raised the question whether merely describing the
microorganism used, and where and how it was found, satisfied the
enablement requirement.3 4 The Patent Office adopted the position
that a description alone did not satisfy enablement because, without
public access to the microorganism, the invention could not be made
and used by one skilled in the art. 35 The Patent Office, therefore,
required inventors to place samples or cultures of the organisms in
depositories accessible to the public.3 6
The Court of Customs and Patent Appeals in In re Argoudelis 37
affirmed the need for the deposit requirement. The court found that,
given the state of the art, the inventors could not "sufficiently disclose
by written word how to obtain the [new] microorganism . . . from
nature. '38 The screening process used in isolating the new organism
was unpredictable.3 9 As a result, a great deal of time and experimen-
tation might be necessary to find the organism, if it could be found at
all.40 If so, this would constitute "undue experimentation." '4' If dupli-
cating an invention requires "undue experimentation," the enable-
ment requirement is not satisfied.42 An inventor, however, could over-
33. Levy and Wendt, Microbiology and a Standard Format for Infra-Red Ab-
sorption Spectra in Antibiotic Patent Applications, 37 J. Pat. Off. Soc'y 855 (1955).
34. See id. at 856.
35. See id. See supra note 19 and accompanying text.
36. See Levy and Wendt, supra note 33, at 857; Ex parte Kropp, 143 U.S.P.Q.
(BNA) 148, 151 (Pat. Bd. App. 1959) (failure to deposit microorganism or to disclose
its source rendered specification insufficient); cf. Ex parte Moersch, 104 U.S.P.Q.
(BNA) 122, 124 (Pat. Bd. App. 1954) (failure to disclose the method of making a key
starting compound for a chemical process rendered specification non-enabling).
37. 434 F.2d 1390, 1392-93 (C.C.P.A. 1970).
38. Id. at 1392.
39. See id. (screening for microorganisms may take a short time or a long time, if
the organism can be found at all); Ex parte Kropp, 143 U.S.P.Q. (BNA) 148, 152
(Pat. Bd. App. 1959) (same).
40. Argoudelis, 434 F.2d at 1392.
41. See id.; Ex parte Kropp, 143 U.S.P.Q. (BNA) 148, 153 (Pat. Bd. App. 1959).
42. See In re Honn, 364 F.2d 454, 463 (C.C.P.A. 1966) (if extensive experimen-
tation is needed to create claimed compound, specification is insufficient to support
claims) (citing Prutton v. Fuller, 230 F.2d 459, 463 (C.C.P.A. 1956)); Ex parte
Kropp, 143 U.S.P.Q. (BNA) 148, 152 (Pat. Bd. App. 1959). The fact that some
experimentation or testing may be required, however, does not render the specifica-
tion non-enabling. Tabuchi v. Nubel, 559 F.2d 1183, 1187-89 (C.C.P.A. 1977)
(screening a known group of microorganisms to find the one that works best is not
undue experimentation); In re Geerdes, 491 F.2d 1260, 1265 (C.C.P.A. 1974) (test-
ing to select proportions and particle sizes from a given group is not undue experi-
mentation).
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come this problem by making the microorganism starting material
available to the public. 43 Thus, a person skilled in the art could freely
obtain a sample of the organism, and by following the patent specifi-
cation, duplicate the invention. 44
II. CHANGES IN TECHNOLOGY AFFECTING THE DEPOSIT REQUIREMENT
When the Patent Office announced the deposit requirement, the
organisms used by inventors, while rare, already existed in nature. 45
The inventor isolated and identified the organism as opposed to creat-
ing a new organism from a set procedure. 46 The method used was as
follows: Based on prior experience, a scientist examined a sample of a
substrate, such as soil, to detect the presence of microorganisms. 47 Any
microorganisms present were isolated from the substrate, and their
traits studied and catalogued. 4 The organisms were then tested for
any useful characteristics, such as the production of antibiotics. 49 If
the microorganism exhibited a useful trait, the scientists attempted to
develop the organism commercially.50 The process using the microor-
ganism or the new and useful product of the process was the subject of
any patent issued.51
Another process used at that time did not discover pre-existing
organisms but instead sought to create new organisms. This process,
however, did not ensure that the same organism would always be
produced.5 2 The process exposed known organisms to mutation-induc-
ing agents, such as radiation or chemicals.5 3 After exposing a culture
of a selected organism to the mutation agent, the culture was tested to
43. Argoudelis, 434 F.2d at 1392-93.
44. In return for obtaining a sample of the microorganism during the life of the
patent, the user may be required to pay a royalty to the inventor. See Brulotte v.
Thys Co., 379 U.S. 29, 33 (1964) ("A patent empowers the owner to exact royalties as
high as he can negotiate with the leverage of that monopoly."). After the patent
expires, however, anyone can reproduce the invention without charge. Id.
45. See Ex parte Kropp, 143 U.S.P.Q. (BNA) 148, 149 (Pat. Bd. App. 1959)
(microorganism isolated from soil sample found on farm in Pennsylvania).
46. Argoudelis, 434 F.2d 1390, 1392 (C.C.P.A. 1970); I. Cooper, supra note 1,
§ 1.01[l], at 1-4 to -6. Isolation of microorganisms is still used today. See U.S. Pat.
No. 4,315,989 (1982).
47. See I. Cooper, supra note 1, § 1.01[1], at 1-4; U.S. Pat. No. 4,315,989
(1982).
48. I. Cooper, supra note 1, § 1.01[l], at 1-4 to -5.
49. Id. at 1-4.
50. See id. at 1-6.
51. See supra notes 29-31 and accompanying text.
52. Behringer, Microorganism Patents, 63 J. Pat. Off. Soc'y 128, 133-34 (1981)
(mutation is a "shot-in-the-dark approach").
53. See I. Cooper, supra note 1, § 1.01[1], at 1-6; Behringer, supra note 52, at
133-34; Demain, supra note 1, at 991; Falkinham, supra note 3, at 1-31 to -32.
1984]
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see if the resulting organisms exhibited any new and useful traits."4 If
so, the organisms were isolated and developed.55
The rarity of the sampled substrate or the unpredictability of the
mutation agents, however, prevented the results of the isolation proc-
ess or mutation experiments from being readily duplicated., Regard-
less of how accurately the isolation or mutation process was described,
no one skilled in the art could consistently duplicate the results. 57 The
patents using the organisms found by these processes therefore could
not be enabling without a deposit of the organism.58
Advances in technology, however, have allowed more predictabil-
ity in the development of new microorganisms. In 1953, Watson and
Crick discovered deoxyribonucleic acid (DNA) to be the basic genetic
material of living organisms. 59 Since then scientists have sought to
understand how DNA functions. 60 By understanding the structure and
function of DNA, scientists hoped to discover ways to manipulate the
genetic compositions of different organisms to create new and useful
forms of life.0 ' In the late 1970's and early 1980's, several methods
were developed to accomplish this goal.
One method uses natural or laboratory-induced gene transfer meth-
ods to transfer the traits of one organism into another, thereby creat-
ing a new organism.6 2 The new organism has the traits of both. 3 The
patent issued to Ananda Chakrabarty is an example of this proce-
dure.64 In developing his new microorganism, Chakrabarty used plas-
mids65-small, independent, self-replicating segments of DNA that
54. See I. Cooper, supra note 1, § 1.01[l], at 1-2, 1-6; Behringer, supra note 52,
at 133-34; Falkinham, supra note 3, at 11-2.
55. See Falkinham, supra note 3, at II-2.
56. See In re Argoudelis, 434 F.2d 1390, 1392 (C.C.P.A. 1970) (isolation process
may take a long or short amount of time if the organism can be found at all);
Behringer, supra note 52, at 133-34.
57. See In re Argoudelis, 434 F.2d 1390, 1392 (C.C.P.A. 1970) (inventor "'cannot
sufficiently disclose by written word how to obtain the microorganism starting
material from nature"); Ex parte Kropp, 143 U.S.P.Q. (BNA) 148, 152 (Pat. Bd.
App. 1959) (reproduction of the invention would require extensive screening that
may or may not isolate the same organism).
58. See In re Argoudelis, 434 F.2d 1390, 1392 (C.C.P.A. 1970); Ex parte Kropp,
143 U.S.P.Q. (BNA) 148, 152 (Pat. Bd. App. 1959).
59. Fox, The DNA Double Helix Turns 30, 222 Science 29 (1983); Watson and
Crick, Molecular Structure of Nucleic Acids, 171 Nature 737 (1953).
60. Blattner, supra note 3, at 720; see Gilbert, DNA Sequencing and Gcne
Structure, 214 Science 1305 (1981).
61. See Abelson, Biotechnology: An Overview, 219 Science 611 (1983).
62. Falkinham, supra note 3, at 11-2.
63. Id.
64. U.S. Pat. No. 4,259,444 (1982).
65. Id.; Falkinham, supra note 3, at HI-2 to -3.
598 [Vol. 52.
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occur in many forms of bacteria. 6 Chakrabarty transferred the plas-
mids containing the genetic code for several traits from different
varieties of bacteria into one host organism.6 7 Thus, a new organism
was created having the characteristics of both the donors and the host
organism."8 Because following the specification would produce con-
sistent results, enablement could be satisfied without a culture de-
posit.69
Other methods that have been developed to alter the genetic com-
position of microorganisms include the use of natural processes, such
as conjugation 70 and the use of temperate viruses. 7' The use of muta-
tion agents continues to be a major method of producing new orga-
nisms.72 Scientists now have a better understanding of how mutations
occur and have developed more specific mutation agents. 73 Thus, the
predictability of this process has been improved. Fusion of organisms
is another process used.74 Finally, scientists have learned to construct
artificial hybrid plasmids which have been used to transfer the genetic
66. I. Cooper, supra note 1, § 1.01, at 1-3; U. Goodenough & R. Levine,
Genetics 561 (1974). Plasmids generally occur only in bacteria and carry the genetic
code for one or more traits. Id. One advantage of using plasmids to tranfer traits is
that the microorganisms do not suffer any adverse affects. See id. (plasmids are
..capable of enjoying an autonomous self-replicating status in the host-cell without
lowering host-cell viability").
67. U.S. Pat. No. 4,259,444 (1981); Behringer, supra note 52, at 128-29;
Falkinham, supra note 3, at 11-2 to -3.
68. See Falkinham, supra note 3, at 11-2 to -3. Chakrabarty transferred the
plasmids coding for hydrocarbon digestion and heavy metal resistance from different
strains of Pseudomonas aeruginosa into one strain creating a new organism capable
of digesting crude oil. Such an organism could help control oil spills. Id. at 11-2 to -3;
U.S. Pat. No. 4,259,444 (1981).
69. See infra notes 76 and accompanying text.
70. I. Cooper, supra note 1, § 1.01, at 1-3. Conjugation is a prbcess by which two
cells join to exchange genetic material. Id.; U. Goodenough & R. Levine, supra note
66, at 395-99. By interrupting the process at a known point, a scientist can select
which traits are transferred and which are not. See id.
71. I. Cooper, supra note 1, § 1.01[2], at 1-9. Temperate viruses are used to
insert new traits into microorganisms because the viruses merge their genetic mate-
rial with the genetic material of the host organism and can be induced to express the
new information along with the host's normal genes. See U. Goodenough & R.
Levine, supra note 58, at 399.
72. See Demain, supra note 1, at 991-93; Falkinham, supra note 3, at 11-2, see,
e.g., U.S. Pat. No. 4,339,539 (1982) (novel microorganism created by mutating
known organisms); U.S. Pat. No. 4,266,035 (1981) (microorganism used in the
treatment of wastewater developed by mutating a known strain of Pseudomonas);
Evans & Sharp, Single Gene Mutations in Tomato Plants Regenerated from Tissue
Culture, 221 Science 949 (1983) (improved variety of tomato produced by mutating
plant tissue culture); Lyons, Pace Quickens in the Search for Ideal Plants, N.Y.
Times, Sept. 27, 1983, at Cl, col. 1.
73. See Demain, supra note 1, at 991; Falkinham, supra note 3, at 11-2.
74. I. Cooper, supra note 1, § 1.01, at 1-3; Demain, supra note 1, at 991. In this
process, the cell walls of the starting organisms are dissolved and the protoplasts
1984]
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code for traits, such as the production of human insulin, into microor-
ganisms. 75
The important feature of many of these techniques is that a new
organism can be faithfully reproduced relying solely on the specifica-
tion.76 This is in contrast to the earlier processes that did not yield
predictable results. Using these new methods, an inventor can create a
new organism and describe the process in such full, clear and concise
terms that others in the field can achieve the same result solely by
following the specification. Thus, enablement may be achieved with-
out a deposit, and accordingly, a culture deposit should not be re-
quired for every patent claiming a microorganism.
III. THE PROBLEMS STEMMING FROM THE DEPOSIT REQUIREMENT
In addition to the changes occurring in the technology of creating
microorganisms, several problems connected with the deposit require-
ment have arisen. These problems, coupled with the technological
changes that allow enablement at times to be met without a deposit,
demand a reconsideration of the deposit requirement.
A. Limiting the Scope of the Patent
The scope of protection given to a patent owner depends upon what
he claims in his patent. 77 An inventor must recite in his claims what he
believes to be his invention.78 In an infringement action, a court will
interpret the claims broadly or narrowly, depending upon the nature
merged. I. Cooper, supra note 1, § 1.01, at 1-3. The resulting organisms bear the
characteristics of both original cells. Id. at 1-3 to -4.
75. U.S. Pat. No. 4,387,162 (1983); U.S. Pat. No. 4,371,625 (1983); U.S. Pat.
No. 4,362,816 (1982); U.S. Pat. No. 4,349,629 (1982); see U.S. Pat. No. 4,332,892
(1982) (process to produce proteins by inserting hybrid plasmids into microorga-
nisms); Falkinham, supra note 2, at 11-3 to -4. This process involves adding or
substituting a foreign gene into a known plasmid and then introducing the hybrid
plasmid into an organism that will accept the plasmid. Id.; see Hitzeman et al.,
Secretion of Human Interferons by Yeast, 219 Science 620 (1983); Mural et al.,
Phaseolin Gene from Bean is Expressed After Transfer to Sunflower via Tumor-
Inducing Plasmid Vectors, 222 Science 476 (1983). Hybrid temperate phages have
also been altered to insert new genes into microorganisms. See U.S. Pat. No.
4,349,629 (1982).
76. See Meyer, Problems and Issues in Depositing Microorganisms for Patent
Purposes, 65 J. Pat. Off. Soc'y 455, 458-60 (1983); U.S. Pat. 4,349,629 (1982)
(process for creating hybrid plasmids and introducing them into microorganisms).
77. Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605, 607 (1950);
Ziegler v. Phillips Petroleum Co., 483 F.2d 858, 869 (5th Cir.), cert. denied, 414
U.S. 1079 (1973).
78. 35 U.S.C. § 112 (1976).
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of the patent79 and the area of technology. s0 The scope of a claim may,
in some instances, be limited to what is deposited."' This has raised a
serious concern that the scope of protection an inventor receives for his
man-made microorganism may be unnecessarily narrowed.8 2 Such
reduced protection may discourage some inventors from seeking pat-
ents: The advantages of keeping the organism a trade secret may
outweigh the reduced protection of a patent.
The cause for this concern is the Patent and Trademark Office
Board of Appeals (Board) decision in Ex parte Jackson.83 The Board
held that an inventor attempting to claim an entire species of natu-
rally occurring microorganisms would be limited instead to the three
different organisms deposited and mutations of those organisms . 4
This decision severely limits the scope of a patent claiming microorga-
nisms when a deposit is required and is a shift from the cases involving
chemical patents in which an inventor may be able to claim an entire
class of compounds.8s5 As a result, similar organisms "discovered" by
another scientist might be found to lie outside the scope of the patent
and be non-infringing.86
While the microorganisms claimed in Jackson were naturally occur-
ring, the language in the opinion appears broad enough to encompass
man-made microorganisms as well.8 7 The problem of applying Jack-
79. The claims in a "pioneer patent," which covers a wholly new function or
device, are entitled to very liberal construction, providing a broad scope of protec-
tion. Westinghouse v. Boyden Power Brake Co., 170 U.S. 537, 561-62 (1898); Ziegler
v. Phillips Petroleum Co., 483 F.2d 858, 870 (5th Cir.), cert. denied, 414 U.S. 1079
(1973). When the patent is merely an improvement on an existing invention, the
claims are construed more narrowly and the inventor is given more limited protec-
tion. Connell v. Sears, Roebuck & Co., 559 F. Supp. 229, 245 (N.D. Ala.), aff'd in
part, 722 F.2d 1542 (Fed. Cir. 1983); see Ziegler v. Phillips Petroleum Co., 483 F.2d
858, 870 (5th Cir.), cert. denied, 414 U.S. 1079 (1973).
80. If the technology has been well developed, the claims will be narrowly
construed. Connell v. Sears, Roebuck & Co., 559 F. Supp. 229, 246 (N.D. Ala.),
aJJ'd in part, 722 F.2d 1542 (Fed. Cir. 1983).
81. Elman, Patent Examiners Cite Unpublished Appeals Decision in Denying
Broad Species Claims, Genetic Engineering News, May/June 1983, at 13, col. 1
(patent claims limited to microorganism deposited); Schmidt, Microorganisms are
Entitled to Generic Claims as Much as Anything Else, 2 Biotechnology L. Rep. 126
(1983) (same).
82. Schmidt, supra note 81, at 131.
83. 217 U.S.P.Q. (BNA) 804 (Pat. Bd. App. 1982).
84. Id. at 807-08.
85. Schmidt, supra note 81, at 128-31; see In re Fischer, 166 U.S.P.Q. (BNA) 18
(C.C.P.A. 1970) (patentee allowed to claim class of chemicals by defining the basic
characteristics of the class).
86. See Schmidt, supra note 81, at 131; cf. Ziegler v. Phillips Petroleum Co., 483
F.2d 858, 868 (5th Cir.) (court will determine if the infringing product is the same as
the patented invention), cert. denied, 414 U.S. 1079 (1973).
87. Ex parte Jackson, 217 U.S.P.Q. (BNA) 804, 809 (Pat. Bd. App. 1982) (Katz,
Examiner-in-chief, concurring) ("Even considering the newly developing biological
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son to the claims of the inventor of a man-made organism is that,
unlike the inventors in Jackson, he has shown how, in effect, to create
a new species of organism."" He should be entitled to claim the entire
species resulting from his process if the specification alone is ena-
bling.89 If the inventor of a man-made microorganism believes that his
claims would be severely limited, he may choose to forego seeking a
patent and instead maintain his invention as a trade secret. 90 This
would contravene the purpose of the Act, which is to encourage
inventors to disclose their discoveries so that others can learn from and
build upon their inventions. 9'
B. The Cost of Depositing Microorganisms
The cost of establishing and maintaining a microorganism deposit is
perhaps the biggest practical problem with the deposit requirement.92
This cost may deter inventors from seeking a patent. No other patent
applicant faces this cost, which runs from $380 to over $870 per
deposit, depending upon the type of protection sought. 93 This cost has
risen considerably over the past few years and may continue to rise.94
In light of the high cost of obtaining a patent,95 the fact that a deposit
engineering techniques, at this time it is just not feasible to expect one skilled in the
art to 'manufacture' the necessary microbe."); see Schmidt, supra note 81, at 131.
88. Schmidt, supra note 81, at 131.
89. See id.
90. See I. Cooper, supra note 1, § 1.02, at 1-16 to -17; Schmidt, supra note 81, at
131.
91. See supra note 17 and accompanying text.
92. See I. Cooper, supra note 1, § 5.04[2], at 5-54 to -55. One author has stated
that while the cost presents a problem, it is cheaper to pay the deposit fee than it is to
prepare "a response to an office action rejecting the application . . . for lack of a
deposit." Id. at 5-55.
93. The fees listed are for the American Type Culture Collection (ATCC), one of
the two major depositories in the United States. The $380 fee is for inventors seeking
U.S. patents. An additional $300 fee is required if the depositor wants to be informed
of all recipients of the deposit. The fee is $870 for those filing under the Budapest
Treaty on the International Recognition of the Deposit of Microorganisms for the
Purposes of Patent Procedure, Apr. 28, 1977, T.I.A.S. No. 9768. American Type
Culture Collection, Patent Culture Depository (1981) [hereinafter cited as ATCC
Pamphlet].
The other major depository in the United States is the Agricultural Research
Culture Collection (NRRL) [hereinafter cited as ARS Collection]. The fee for depos-
iting a culture at the ARS collection is $500 regardless of the type of protection
sought. ARS Patent Culture Collection Initiation of Fees!, 1033 Official Gaz. Pat.
Off. 22 (Aug. 23, 1983) [hereinafter cited as ARS Collection Fees].
94. Prior to 1983, the ARS Collection did not charge any fees for depositing
microorganisms for patent purposes. See ARS Collection, Procedures and Policies for
Deposition of Cultures for Patent Purposes in the Agricultural Research Culture
Collection (NRRL) 1 (1979).
95. In addition to the deposit fees, other expenses connected with a patent
application include Patent Office fees that can exceed $1000. See 35 U.S.C.A. § 41
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can increase that cost by five to ten percent may present a significant
obstacle to many new biotechnology companies. To achieve and
maintain a strong market position and thereby attract more customers
and investors,96 these companies should establish extensive patent
portfolios.9 7 Biotechnology companies usually have very limited capi-
tal with which to develop a patent portfolio. Needlessly increasing the
cost of securing a patent would unnecessarily cause some companies to
fail and force others to pursue other forms of protection such as trade
secrets.
The cost may be increased further if an inventor is required to make
several deposits to ensure the broadest possible scope for his patent in
light of Jackson.98 An inventor may be required to deposit every
possible organism created by his process or at least a sufficient number
of new microorganisms to show that he has created a process that
should be afforded broad scope. 99 Given the current costs for deposit-
ing microorganisms, this can increase significantly the costs of secur-
ing patent protection and may discourage some inventors from seeking
patents. 100
C. Lack of a Precise Standard for the Requirement
While the Patent Office and the two major depositories have some
rules concerning the deposit requirement, the rules are incomplete
and varied. 1' 1 In addition, the Manual of Patent Examining Proce-
dure merely lists guidelines for the preferred way to meet the deposit
requirement. 102 Other methods of meeting the requirement are possi-
ble. 10 3 This lack of standards presents various problems, including the
(1982); 37 C.F.R. § 1.16-1.21 (1983). Attorneys fees can bring the total cost to over
$4000. See Am. Pat. Law Ass'n, Report of Economic Survey 13, 30-31 (Oct. 1983).
96. See supra note 6 and accompanying text.
97. See Norman, supra note 4, at 1016-17; see also Schmeck, Report Says Japan
Could Lead in Commercial Biotechnology, N.Y. Times, Jan. 27, 1984, at A9, col. 3
(U.S. companies have difficulty in obtaining capital for later rounds of financing).
98. See supra notes 83-86 and accompanying text.
99. See supra notes 83-86 and accompanying text.
100. See supra notes 83-86 and accompanying text.
101. Among the differences are the fees, see supra note 93 and accompanying text,
and what organisms will be accepted. The ARS Collection will not accept "[v]iruses
and highly pathogenic or especially fastidious microorganisms." ARS Collection
Fees, supra note 93, at 23. The ATCC has no such restriction. See ATCC Pamphlet,
supra note 93; I. Cooper, supra note 1, § 5.03[3], at 5-52.
102. MPEP, supra note 20, § 608.01(p)(C); I. Cooper, supra note 1, § 5.02[9], at
5-23; Biggart, Patentability in the United States of Microorganisms, Processes Utiliz-
ing Microorganisms, Products Produced by Microorganisms and Microorganism Mu-
tational and Genetic Modification Techniques, 22 Idea 113, 122-23 (1981).
103. See Feldman v. Aunstrup, 517 F.2d 1351, 1355 (C.C.P.A. 1975) (deposit that
did not meet all the MPEP guidelines for culture deposits found to be acceptable
because it fulfilled the purpose of the deposit requirement), cert. denied, 424 U.S.
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possible release of the deposited organism prior to the issuance of a
patent.
If a culture deposit is required it must be made on or before filing a
patent application.0 4 Normally, during the examination of a patent
application, the Patent Office is required to keep secret the applica-
tion and accompanying materials. 05 The information disclosed to the
Patent Office becomes public only if the patent issues. 106 Should a
patent not issue, the inventor may retain trade secret rights in the
invention. 10 7 The Patent Office has developed specific rules that are
intended to ensure the secrecy of applications before it. 08
Unfortunately, the Patent Office does not possess the facilities to
maintain culture deposits. 0 9 Therefore, other agencies of the federal
government," 0 private corporations"' and institutions 1 2 maintain the
deposits. The lack of set procedures for ensuring the confidentiality of
deposits means secrecy at these institutions may be difficult to main-
tain. 1 3 Even a governmental facility, while acknowledging the neces-
sity for maintaining secrecy, l l4 has not adopted any rules or proce-
dures to do so.1l5 When viewed in light of the recent incidents in
which companies have obtained their competitors' trade secrets given
confidentially to the federal government, 116 genuine concern for the
secrecy of the deposits arises.
912 (1976); I. Cooper, supra note 1, § 5.02[9], at 5-23 to -25, § 5.03, at 5-47 to -52;
Biggart, supra note 102, at 124-25.
104. MPEP, supra note 20, § 608.01(p)(C).
105. See 35 U.S.C. § 122 (1976).
106. See 37 C.F.R. § 1.11 (1983).
107. See, e.g., Aronson v. Quick Point Pencil Co., 440 U.S. 257, 264-65 (1979)
(denial of a patent did not affect the inventor's right to enforce a contract for
payment of a royalty based on a trade secret disclosure); Kewanee Oil Co. v. Bicron
Corp., 416 U.S. 470, 482 (1974) (non-patentable discovery can be protected as a
trade secret).
108. See 37 C.F.R. § 1.14 (1983).
109. See I. Cooper, supra note 1, § 5.02[8], at 5-22.
110. The ARS Collection is maintained by the Department of Agriculture. Reorg.
Plan No. 1 of 1947, 12 Fed. Reg. 4534 (1947), reprinted in 5 U.S.C. app. at 731
(1976) and in 61 Stat. 952 (1947) (all agricultural research functions consolidated
under the Secretary of Agriculture).
111. One such corporation is In Vitro International, Inc. See Acquisition of the
Status of International Depositary Authority, Indus. Prop., Nov. 1983, 'at 306, 307.
112. The ATCC is a private, non-profit corporation. I. Cooper, supra note 1,
§ 5.0312], at 5-50.
113. This is analogous to the trade secrets situation where the absence of set
guidelines or procedures for safeguarding the protected material increases the chance
of disclosure. See R. Milgrim, Trade Secrets § 2.04, at 2-27 (1983).
114. See ARS Collection, Procedures and Policies for Deposition of Cultures for
Patent Purposes in the Agricultural Research Culture Collection (NRRL) 1 (May
1979).
115. Id. at 4.
116. Cf. Monsanto Co. v. Acting Adm'r, United States EPA, 564 F. Supp. 552,
567 (E.D. Mo.) (disclosure by the EPA of Monsanto's secret formulas for insecticides
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The lack of a clear standard also creates a problem regarding the
nature of the deposit. In some cases, the inventor deposited only the
organism created or found. 11 7 In another case, the inventor deposited
the organism that donated the plasmid he used, as well as the new
organism developed using that plasmid. "8 In yet another instance, the
applicant deposited the starting organism. " 9 These examples raise the
question of which of the many materials used the inventor should
deposit to allow others to make and use his invention. If, in hindsight,
a court finds that the inventor has failed to deposit the correct mate-
rial, the patent may be held invalid for failing to fulfill the enable-
ment requirement. 20
As a result of this possibility, the cost of the deposit again becomes a
factor. To ensure meeting the enablement requirement, an inventor
may feel compelled to deposit every material or organism used in his
invention.' 2' This practice increases the cost of the patent because
each deposit requires a separate fee. 22 If the inventor had to make
only one deposit based on a clear standard, the cost would be reduced.
In light of these problems, changes in the deposit requirement are
needed. Additionally, the changes in technology that often make a
specification by itself enabling cast doubt on the need for a deposit in
every case.
IV. PROPOSED CHANGES IN THE DEPOSIT REQUIREMENT
A. Elimination of the Deposit Requirement in Some Cases
Eliminating the deposit requirement in certain circumstances
would alleviate many of the problems previously detailed.12 3 Unfortu-
found to be an unconstitutional taking of plaintiff's property), probable jurisdiction
noted sub nom. Ruckelshaus v. Monsanto Co., 52 U.S.L.W. 3290 (U.S. Oct. 18,
1983); Airborne Data Inc. v. United States, 216 U.S.P.Q. (BNA) 887, 893-94 (Ct. Cl.
1982) (U.S. Geological Survey disclosed trade secrets of a contract bidder to its
competitors despite agreement to the contrary), aff'd, 217 U.S.P.Q. (BNA) 297 (Fed.
Cir. 1983).
117. See, e.g., U.S. Pat. No. 4,363,876, col. 1 (1982); U.S. Pat. No. 4,350,769,
col. 1 (1982).
118. See U.S. Pat. No. 4,362,816, col. 3 (1982).
119. U.S. Pat. No. 4,378,655, col. 10 (1983).
120. See Shelco, Inc. v. Dow Chemical Co., 322 F. Supp. 485, 517 (N.D. Ill.
1970) (failure to include or disclose an essential element relating to the composition,
manufacture or use of the invention will render the patent invalid), aff'd on other
grounds, 466 F.2d 613 (7th Cir.), cert. denied, 409 U.S. 876 (1972).
121. See supra notes 98-100 and accompanying text.
122. See ATCC Pamphlet, supra note 93; ARS Collection Fees, supra note 93, at
22.
123. See supra pt. III. At least one country, Sweden, has amended its patent laws
to read that if the specification can enable one skilled in the art to reproduce the
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nately, the deposit requirement can be eliminated or avoided only
when a narrow set of circumstances exist. The process of creating or
isolating the microorganism should be capable of being easily dupli-
cated based upon the specification. The specification should include,
among other things: the nature and source of the starting materials,
the enzymes or chemical agents used, the steps and conditions for each
step of the process, and an explanation of how the organism was
induced to exhibit its new traits. 124 A showing that others skilled in the
art, by following the specification, can duplicate the invention faith-
fully and with little difficulty should be required to ensure that the
specification alone is enabling.1 25 On the other hand, patents relying
on naturally occurring microorganisms that cannot be readily isolated
from nature or man-made microorganisms created by a process that
cannot be readily duplicated should still require a deposit. No matter
how well the inventor describes the procedure for creating or isolating
the organism, if one skilled in the art can not easily follow it or
produce the same results, the enablement requirement has not been
met. 126
invention, no culture deposit is required. Ass'n Of Swedish Patent Att'ys, Amend-
ments of the Swedish Patents Act (August 1983) (available in files of Fordharn Law
Review).
124. I. Cooper, supra note 1, § 5.06[2], [3].
125. Affidavits or declarations by other scientists skilled in the art that they have
read and followed the specification to recreate the invention without difficulty would
be sufficient. See R. Saliwanchik, Legal Protection for Microbiological and Genetic
Engineering Inventions 122-23 (1982). Affidavits for this purpose are common in
patent application procedures. See 37 C.F.R. § 1.132 (1983) (affidavits can be used
to traverse a rejection for inoperative specification). The process should work every
time or the disclosure is inadequate. Standard Oil v. Montedison, 494 F. Supp. 370,
384 (D. Del. 1980), aff'd, 664 F.2d 356 (3d Cir. 1981), cert. denied, 456 U.S. 915
(1982).
126. In re Argoudelis, 434 F.2d 1390, 1392 (C.C.P.A. 1970). See supra notes 37-44
and accompanying text. Because of the wording of many foreign patent acts, a
deposit may be required in cases in which patent protection is sought in those
countries. See I. Cooper, supra note 1, § 5.02[16], [17], [18]; R. Saliwanchik, supra
note 125, at 147-59.
Arguably, a deposit may be required in all cases to satisfy the "best mode"
requirement of § 112. I. Cooper, supra note 1, § 5.04[2], at 5-55. The "best mode"
concept stems from the part of § 112 requiring an inventor to set forth the "best
mode" contemplated by him for carrying out the invention. See 35 U.S.C. § 112
(1976). The purpose of the requirement is to insure that the inventor discloses the best
embodiment of his invention at the time he applies for his patent. See In re Gay, 309
F.2d 769, 772 (C.C.P.A. 1962). A deposit might be required under this concept if the
invention was a process using a microorganism instead of creating a microorganism.
This is because the best way of recreating the process is to obtain a sample of the
organism from a public depository. If the invention, however, is not a process using
an organism but the organism itself the inventor may satisfy the best mode require-
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Not requiring a deposit in certain circumstances would alleviate the
problems created by Ex parte Jackson. 27 Jackson is viewed as severely
limiting the scope of a patent claiming a microorganism. 128 The Board
reasoned in part that the specification and the deposited microorga-
nism did not adequately instruct those skilled in the art how to find
the other members of the species being claimed.12 9 This rationale,
however, should not apply to the inventor of a man-made microorga-
nism when the specification is sufficiently enabling to eliminate the
deposit requirement. Such an inventor has shown how to create a new
organism. The process can be used to create other organisms with
similar traits. 130 The inventor has created a new species defined by the
traits he has transferred into the organism created. On the other hand,
inventors claiming a naturally occurring microorganism, such as the
scientists in Jackson, have shown how to obtain only the organism
claimed and not the rest of the species. 13' Accordingly, Jackson would
still apply and the rationale for limiting the scope of the patent would
still be correct.
B. Postponement of Deposit Until the Patent is Allowed
If a deposit is required, it should be required only after the notice of
allowance is issued. In this manner, an inventor would be spared the
cost of the deposit until he is sure of receiving a patent. 132 Addition-
ally, should a patent not issue, it would be easier for an inventor to
ment by disclosing the best way to make and use the organism. Id.; Herbert, Failure
to Disclose the "Best Mode": What the Public Doesn't Know Will Hurt Them, 64 J.
Pat. Off. Soc'y 12, 18-19 (1982).
127. 217 U.S.P.Q. (BNA) 804 (Pat. Bd. App. 1982). See supra notes 83-91 and
accompanying text.
128. See supra notes 81-91 and accompanying text.
129. See Ex parte Jackson, 217 U.S.P.Q. (.BNA) at 806; Schmidt, supra note 81, at
127.
130. See Meyer, supra note 76, at 460-61.
131. 217 U.S.P.Q. (BNA) at 806. It may be argued that the inventors in Jackson
had in fact found a new species just as the inventor of a man-made organism has
created a new species defined by the traits he has been able to transplant. Therefore a
claim to the entire species should be allowed. See Schmidt, supra note 81, at 128.
This, however, does not resolve the problem of instructing others skilled in the art to
find the rest of the species.
Jacks-on, however, may not be as limiting as it appears. The Board did hold that
the scope of the claims would include mutations of the strains deposited. 217
U.S.P.Q. (BNA) at 806. Because mutation of patented organisms is the most likely
avenue for the development of infringing organisms, this should be sufficient cover-
age. Id.; accord BLR Interviews Author of Treatise on Patenting Biotechnology
Inventions, 2 Biotechnology L. Rep. 106, 111 (1983).
132. Fees are not required until the deposit is made. See supra note 93 and
accompanying text. The issuance of a notice of allowance means that the patent
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maintain his trade secret because there is less risk of a sample of the
microorganism falling into the hands of a third party. 33
Arguably, a deposit should be required at the time of filing, to
ensure that the organism claimed has actually been created. 34 This,
however, can be accomplished without a deposit. If the Patent Office
suspects that the organism claimed does not exist, a sample can be
requested. 35 The Patent Office can then have the culture tested in a
governmental laboratory. 136
C. A Standard for the Deposit
The adoption of a clear standard for culture deposits by the Patent
Office and the authorized depositories would help solve many of the
problems. 37 An example of such a set of rules is the Budapest Treaty
on the International Recognition of the Deposit of Microorganisms for
the Purposes of Patent Procedure (Treaty). 38 While not requiring all
depositors to comply with the Treaty, the two major American depos-
itories, as authorized Treaty facilities, are familiar with the require-
ments. 3 Thus, no new rules or regulations would need to be devel-
oped.
application has been approved and a patent will issue once the necessary fees are paid
and formalities are met. 37 C.F.R. §§ 1.311(a), 1.314 (1983).
133. Not having a deposit in the hands of a third party makes it easier to keep the
invention a secret, which is the key to trade secret protection. See I. Cooper, supra
note 1, § 1.02, at 1-16.
134. Part of the ARS Collection depositing procedure requires the laboratory to
test the culture to see if the organism is viable. ARS Collection, supra note 114, at 4.
135. 35 U.S.C. § 114 (1976) allows the Patent Commissioner to require an appli-
cant to furnish the Patent Office with models, specimens or ingredients for the
purpose of inspection or experimentation.
136. The Patent Office has limited facilities, but it may be able to arrange to have
another agency, such as the Department of Agriculture, test the cultures. See I.
Cooper, supra note 1, § 5.02[8], at 5-22.
137. See supra pt. III. Perhaps the one problem that cannot be eliminated is the
cost of the deposit.
138. Apr. 28, 1977, T.I.A.S. No. 9768, reprinted in 961 Official Gaz. Pat. Off. 21
(1977) [hereinafter cited as Budapest Treaty]. While the Patent Office and the major
depositories do follow the Treaty for some applications, there is no requirement that
the Treaty be used. See MPEP, supra note 20, § 608.01(p)(C).
139. See I. Cooper, supra note 1, § 5.02[16]. Recently, a third United States
depository, In Vitro International, Inc., has achieved Treaty facility status. Acquisi-
tion of the Status of International Depositary Authority, Indus. Prop., Nov. 1983, at
306, 307.
Other Treaty facilities include: National Collection of Yeast Cultures (United
Kingdom); the Fermentation Research Institute (Japan); the Deutsche Sammelung
von Mikroorganismen (Federal Republic of Germany); and the Centraalbureau vor
Schimmelcultures (Netherlands). I. Cooper, supra note 1, § 5.02[16], at 5-44. A
deposit in any of these facilities will satisfy the United States deposit requirement. See
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The Treaty rules detail the manner in which the microorganism
should be deposited, 140 how long the deposit should be maintained, 41
and the procedures for ensuring the secrecy of the deposit.' 42 Thus,
these rules would eliminate many of the problems with the deposit
requirement. 43 To ensure that the rules are followed, the Patent
Office should require that the organism be deposited in a Treaty
facility and that the Treaty requirements be satisfied before the patent
will issue.
The Treaty does not address what organisms or material should be
deposited if a deposit is needed. 144 Moreover, there are currently no
clear enablement guidelines covering this point.145 The Patent Office
should provide guidelines to which an inventor can look in order to
satisfy enablement. Because of the nature of the inventions, however,
set requirements would be difficult to provide. Whether a deposit
satisfies the enablement requirement would still have to be judged on
a case-by-case basis. The main benefit in providing guidelines, how-
ever, is not in giving the inventor a list of requirements. Rather, if an
inventor's patent is challenged, he will be able to point to the guide-
lines and show that he satisfied them to the best of his ability. This
would be in contrast to the "shotgun" approach that some inventors
use to ensure compliance. 146 The guidelines should be based on com-
mon sense: The inventor should deposit organisms or materials that
are not readily available or that cannot be made by following the
inventor's written procedure. 47 In this manner, the inventor can be
assured of satisfying the enablement requirement with the fewest
possible deposits.
CONCLUSION
While some patents claiming microorganisms still must meet the
deposit requirement, recent developments in biotechnology allow
Feldman v. Aunstrup, 517 F.2d 1351, 1356 (C.C.P.A. 1975), cert. denied, 424 U.S.
912 (1976).
140. Rules 6, 7, Budapest Treaty, supra note 138, at 15-16, reprinted in 961
Official Gaz. Pat. Off. at 32-33 (1977).
141. Rule 9, Budapest Treaty, supra note 138, at 17, reprinted in 961 Official
Gaz. Pat. Off. at 33-34.
142. Rules 9.2, 11, Budapest Treaty, supra.note 138, at 17-19, reprinted in 961
Official Gaz. Pat. Off. at 34.
143. See supra pt. III.
144. See Budapest Treaty, supra note 138.
145. See supra notes 117-20 and accompanying text.
146. See supra notes 117-20 and accompanying text.
147. Cf. Ex parte Moersch, 104 U.S.P.Q. (BNA) 122, 123-24 (Pat. Bd. App. 1954)
(specification would have been sufficient had the source of the compound been made
known before or at the time of filing).
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many inventors to satisfy the enablement requirement with the speci-
fication alone. Additionally, serious problems with the deposit re-
quirement exist. These problems reinforce the proposition that a de-
posit should not be required if it is not needed.
Adoption of a clear set of standards for the deposit, such as the
Budapest Treaty, will eliminate many problems for those patents still
needing a deposit. Deferring a deposit until the notice of allowance is
issued will reduce the problem of possible disclosure prior to the
issuance of the patent. Adoption of these suggestions will encourage
inventors of new microorganisms to seek patent protection and thus
further the purposes of the Patent Act.
John Edward Schneider
